Seek immediate medical attention (call 999 or go to A&E) if you experience: A seizure or convulsion for the first time Loss of consciousness or altered awareness Severe, persistent headache, especially if accompanied by visual changes, confusion, or neck stiffness Signs of severe hypoglycaemia (confusion, difficulty speaking, loss of coordination) Symptoms of severe dehydration (reduced urination, extreme thirst, dizziness, rapid heartbeat) Contact your GP or healthcare provider if you experience: New or worsening headaches that don't respond to simple analgesia Persistent dizziness affecting daily activities Unusual fatigue or weakness Any neurological symptoms that concern you Patients should not discontinue Wegovy without discussing with their healthcare professional, as clinical review is advised when stopping treatment
A flow chart outlining the step-by-step sampling design for both trials is provided in Fig
The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks
There is no clinical evidence that microdosing semaglutide is safer than weekly dosing
